Prevalence of and factors associated with extraintestinal manifestations and their remission in inflammatory bowel disease: the EXTRA prospective study from the GETAID.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
13
02
2023
accepted:
23
05
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
aheadofprint
Résumé
Extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors for EIMs. Study aimed to prospectively investigate the epidemiology, risk factors for EIM occurrence and EIM remission in a large IBD cohort. We conducted a cross-sectional study in 30 French referral centers. Between May to June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire. A total of 1971 consecutive patients with IBD were analyzed. There were 1056 women (53.8%), and the median age of patients was 41 years [31; 54]. The median disease duration was 11 years [1; 18]. Overall, 544 (27.6%) had at least one EIM. In 20.2% of case, patient had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (OR=2.56; p<0.001) was a risk factor for EIM, while the Montreal A3 classification (OR=0.61, p=0.023) and male gender (OR=0.61, p<0.001) were associated with a lower risk for EIM occurrence. IBD current clinical remission (OR=2.42; p<0.001) and smoking cessation (OR=2.98; p<0.001) were associated factors for EIM remission. Conversely, age at IBD diagnosis (OR=0.98; p<0.018) was associated with a lower risk of EIM remission. One quarter of patients had at least one EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors for EIMs. Study aimed to prospectively investigate the epidemiology, risk factors for EIM occurrence and EIM remission in a large IBD cohort.
METHODS
METHODS
We conducted a cross-sectional study in 30 French referral centers. Between May to June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire.
RESULTS
RESULTS
A total of 1971 consecutive patients with IBD were analyzed. There were 1056 women (53.8%), and the median age of patients was 41 years [31; 54]. The median disease duration was 11 years [1; 18]. Overall, 544 (27.6%) had at least one EIM. In 20.2% of case, patient had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (OR=2.56; p<0.001) was a risk factor for EIM, while the Montreal A3 classification (OR=0.61, p=0.023) and male gender (OR=0.61, p<0.001) were associated with a lower risk for EIM occurrence. IBD current clinical remission (OR=2.42; p<0.001) and smoking cessation (OR=2.98; p<0.001) were associated factors for EIM remission. Conversely, age at IBD diagnosis (OR=0.98; p<0.018) was associated with a lower risk of EIM remission.
CONCLUSION
CONCLUSIONS
One quarter of patients had at least one EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.
Identifiants
pubmed: 37523417
doi: 10.14309/ctg.0000000000000607
pii: 01720094-990000000-00180
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.